Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : CEAPRO INC.----CZO -- Ignore unavailable to you. Want to Upgrade?

To: PJ who wrote (14)	6/22/1998 3:13:00 PM
From: PJ	Read Replies (1) \| Respond to of 53

CEAPRO INC. - CANDERM PHARMA INC. IS LICENSED TO SELL LIPSOREX(TM) Standard & Poors No. 12G Reg.823486 EDMONTON, June 5 /CNW/ - Ceapro Inc. (''Ceapro'') (ASE: CZO) announced today that the Company has issued an exclusive license to a Montreal-based firm, Canderm Pharma Inc., to sell Lipsorex(TM) in Canada with an 8% royalty payment on sales and rights of first refusal for an American and European license within four years. Established in 1972, Canderm, a family-owned and managed company, is Canada's largest independent skin care company. Canderm specializes in cosmeceuticals, ethical dermatologicals, and wound care products. Some products in their line-up include Bain de Soleil, NeoStrata, Condyline, UltraMOP, Ultraquin, Dermagran II, Epi-Derm, and Omiderm. The past two years Canderm has been listed in Profit Magazine as one of Canada's fastest growing companies, with 11 sales representatives and 45 brokers across Canada. Ceapro is pleased to do business with this exceptional company. Canderm's projections on profitability and sales from Lipsorex are excellent. Lipsorex has also had its patent approved for the U.S. this year. Ceapro is a life sciences company engaged in the research, development, and marketing of products that are primarily oat based. Their current focus is on medical diagnostics specializing in diabetes type 2, human and animal dermal care, and marketing international products based on biologically active oat extracts and natural compounds. Ceapro is based in Edmonton and is listed on the Alberta Stock Exchange under the trading symbol CZO. The ASE has neither approved nor disapproved of this release dated June 5, 1998. -30- For further information: R.A. (Bob) Binnendyk, President and CEO, Ceapro Inc., (403) 421-4555, Barry Vogel, President, Canderm Pharma Inc., (514) 334-3835, Carol Palmason, Senior Vice President, Pharmaceuticals, Ceapro Inc., (403) 421-4555